PureTech Health's Vor wins FDA fast-track approval for cancer drug
PureTech Health
212.50p
16:44 25/04/24
0.00%
0.00p
Clinical stage biotherapeutics firm PureTech Health on Friday said its founded entity, Vor Biopharma, had won US fast track approval for its leukaemia treatment.
FTSE 250
19,601.98
17:09 25/04/24
n/a
n/a
FTSE 350
4,434.34
17:09 25/04/24
n/a
n/a
FTSE All-Share
4,387.94
16:49 25/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,750.48
17:09 25/04/24
3.90%
852.98
The US Food and Drug Administration granted the designation to VOR33, a hematopoietic stem cell therapeutic candidate for the treatment of acute myeloid leukaemia.